The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

December 07, 2009 07:00 ET

Medipattern and PenRad to Install 1st B-CAD® PenLink™ At Zwanger-Pesiri Radiology

TORONTO, ONTARIO--(Marketwire - Dec. 7, 2009) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, and PenRad Technologies, Inc. ("PenRad"), a leader in the development of mammography information systems (MIS) are pleased to announce the first installation of the new PenLink connectivity package at Zwanger-Pesiri Radiology, Long Island's largest private medical imaging practice. This PenLink installation will be the first center in the world to integrate the benefits of automated ultrasound reporting from B-CAD with the PenRad comprehensive MIS required to maintain state of the art quality control for Breast Imaging. Medipattern announced their collaboration with PenRad in a press release dated November 26, 2009. The first products resulting from the collaboration are PenLink and PenView. PenLink reads the information from the B-CAD breast ultrasound report and automatically enters the CAD results into PenRad Technologies' PenRad™ Reporting System, dramatically improving clinical and reporting workflow.

"Having B-CAD directly feed PenRad is a phenomenal jump in productivity and simplifies workflow. The CAD results are automatically populated directly into the radiologist report. The radiologist can then review images, CAD findings, edit and document the case," commented Steven Mendelsohn, MD medical director and co-owner of Zwanger-Pesiri. "This saves time on every breast ultrasound exam, while increasing consistency and accuracy with B-CAD."

Zwanger-Pesiri provides state of the art services to the communities of Nassau and Suffolk Counties in New York in eight locations. Zwanger-Pesiri was founded in 1953 with the purpose of providing referring physicians and patients on Long Island with modern medical diagnostics. The practice was the first in the area to offer specialized imaging with a 3 Tesla MRI, first with 128 slice CT following on in the tradition of providing leading edge, innovative medicine to better care for the community.

"This is the first of a series of products designed to combine the power of CAD with broad based MIS clinical reporting. All of these products define a new level of integration that is made possible through our collaborative agreement," added Jeff Collins, President and CEO of The Medipattern Corporation. "We are pleased that our efforts with PenRad have generated an immediate response. We would also like to congratulate our reseller Amy Eriksen of Physicians Consultant Medical Sales of New York for facilitating this transaction."

About PenRad Technologies, Inc.:

PenRad is a provider of mammography information solutions (MIS) including a wide array of products from the flagship PenRad reporting system product to PenScan, PenProfiler, PenFetch, PenConnect, PenTrac and PenView. The PenRad mammography reporting/mammography tracking system decreases workload, increases efficiency and offers immediate turnaround time for exams. For more information, please visit www.penrad.com.

About The Medipattern Corporation:

Medipattern® (TSX VENTURE:MKI) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: www.medipattern.com.

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation. PenLink, PenView and PenRad are trademarks of PenRad Technologies. BI-RADS is a registered trademark of the American College of Radiology.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information